The primary mission of Core A is to provide leadership, coordination and integration of all the components of the UK-ADC, so that our programmatic and scientific goals are achieved. Our overall scientific objective is to support and facilitate research aimed at elucidating the pathogenic mechanisms underlying the transitions from normal cognitive aging to the development of AD, with a long-term goal of enabling more effective translation of this mechanistic knowledge to intervention strategies. The UK-ADC has historically been at the forefront of supporting research in identification of the early manifestations of disease and the pathogenic mechanisms underlying the transitions from normal cognitive aging to the development of AD. In the renewal period, we will build upon this highly successful focus, as well as leverage several recent positive developments at UK that will expand our translational research capability, and thereby help to increase the rate of progress toward new therapies to delay or prevent AD. The UK-ADC functions in a multidisciplinary, integrated, and supportive environment that catalyzes high-quality AD research within the UK community and throughout Kentucky and beyond. The ADC also enhances education and outreach within UK and in the community, and provides clinical diagnoses and care of patients with cognitive impairment. The ADC serves as the focal point of all AD-related activities in Kentucky, providing the infrastructure and resources to enhance scientific interactions and develop new collaborations. The ADC also reaches beyond Kentucky to enhance AD research, education, and clinical practice on a national level through its interactions with other ADCs, as well as other regional and national institutions, including the Alzheimer's Association, NIA and industry. An effective Administrative Core is essential for transforming ADC goals into accomplishments. Therefore, Core A will continue to support the ability of our UK-ADC to serve as a critical resource for the university, community, state, region and nation through a set of integrated and intertwined specific aims.
Aim 1 : Provide leadership and an organizational framework for management and coordination of all ADC activities to ensure optimal resource utilization to meet the overall goals of the ADC.
Aim 2 : Enable the ADC to serve as the focal point of AD-related activities in Kentucky by continuing to coordinate, facilitate, and promote scientific interactions.
Aim 3 : Contribute to and interact with other ADCs and other national collaborative activities and the lay community, to increase visibility of the ADC and maximize progress in AD research throughout the country.

Public Health Relevance

Our goal is to catalyze outstanding AD research while ensuring more rapid progress toward new therapies to delay or prevent AD, so that our human volunteers, patients and caregivers become the beneficiaries of our advances in knowledge. Our well integrated center is moving the field of cognitive aging and AD forward and supporting the elucidation of mechanisms of disease progression so that successful interventions can be developed in the future to treat or prevent this most dehumanizing disorder to affect humans.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG028383-08
Application #
8491995
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
8
Fiscal Year
2013
Total Cost
$210,144
Indirect Cost
$68,633
Name
University of Kentucky
Department
Type
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Lai, Dongbing; Xu, Huiping; Koller, Daniel et al. (2016) A MULTIVARIATE FINITE MIXTURE LATENT TRAJECTORY MODEL WITH APPLICATION TO DEMENTIA STUDIES. J Appl Stat 43:2503-2523
Tanifum, Eric A; Ghaghada, Ketan; Vollert, Craig et al. (2016) A Novel Liposomal Nanoparticle for the Imaging of Amyloid Plaque by Magnetic Resonance Imaging. J Alzheimers Dis 52:731-45
Eitan, Erez; Hutchison, Emmette R; Marosi, Krisztina et al. (2016) Extracellular Vesicle-Associated Aβ Mediates Trans-Neuronal Bioenergetic and Ca(2+)-Handling Deficits in Alzheimer's Disease Models. NPJ Aging Mech Dis 2:
Ebbert, Mark T W; Boehme, Kevin L; Wadsworth, Mark E et al. (2016) Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk. Alzheimers Dement 12:121-9
Scheff, Stephen W; Ansari, Mubeen A; Mufson, Elliott J (2016) Oxidative stress and hippocampal synaptic protein levels in elderly cognitively intact individuals with Alzheimer's disease pathology. Neurobiol Aging 42:1-12
Abner, Erin L; Nelson, Peter T; Kryscio, Richard J et al. (2016) Diabetes is associated with cerebrovascular but not Alzheimer's disease neuropathology. Alzheimers Dement 12:882-9
Day, Gregory S; Musiek, Erik S; Roe, Catherine M et al. (2016) Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study. JAMA Neurol 73:1125-32
LeVine 3rd, Harry; Walker, Lary C (2016) What amyloid ligands can tell us about molecular polymorphism and disease. Neurobiol Aging 42:205-12
Ronquillo, Jay Geronimo; Baer, Merritt Rachel; Lester, William T (2016) Sex-specific patterns and differences in dementia and Alzheimer's disease using informatics approaches. J Women Aging 28:403-11
Segerstrom, Suzanne C; Geiger, Paul J; Boggero, Ian A et al. (2016) Endogenous Cortisol Exposure and Declarative Verbal Memory: A Longitudinal Study of Healthy Older Adults. Psychosom Med 78:182-91

Showing the most recent 10 out of 317 publications